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Abstract
Background
It remains unclear if naltrexone combined with psychotherapy is superior to naltrexone alone
in treating alcohol use disorders (AUD). The current meta-analysis examined the hypothesis
that psychotherapy is a significant moderator that influences AUD-related outcomes and that
naltrexone combined with psychotherapy is associated with significantly better AUD-related
outcomes than naltrexone alone.
Methods
A total of 30 studies (Nnaltrexone = 2317; Nplacebo = 2056) were included. Random effects model
meta-analyses were carried out for each of the studied outcomes. Subsequently, the random
effects model pooled estimates from studies with and without psychotherapy were compared
using a Wald test. A mixed-effect model, incorporating psychotherapy as a moderator, was used
to examine the impact of psychotherapy on treatment outcomes.
Results
Naltrexone had a significant treatment effect on abstinence relapse and Gamma-Glutamyl
Transferase levels, but not cravings. The pooled estimates for studies with and without
psychotherapy were not significantly different for any of the studied outcomes. Psychotherapy
was not a significant moderator in the mixed effects models for any of the studied outcomes.
Conclusions
Naltrexone treatment is efficacious in reducing alcohol consumption, but not reducing
cravings. Adding psychotherapy on top naltrexone did not result in any significant additional
benefit for AUD patients.
Categories: Psychiatry, Psychology, Miscellaneous
Keywords: alcohol use disorder, naltrexone, psychotherapy, abstinence, relapse, gamma-glutamyl
transferase, cravings
Introduction
Alcohol use disorders (AUD) are debilitating psychiatric illnesses characterized by the abuse of
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and dependence on alcohol. The lifetime prevalence of AUD is estimated to be at 29.1%.
AUD bring about devastating consequences to the individual. They are associated with a high
disease-related burden – chronic alcohol consumption is causally implicated in cancer,
cardiovascular disease, liver cirrhosis, and injury. On top of that, an estimated 3.8% of deaths
and 4.6% of disability life years are attributable to alcohol. At the societal level, the economic
costs associated with AUD amounts to at least 1% of the gross national product in high and
middle-income countries. Given such consequences, the need to treat AUD cannot be
understated. Ever since naltrexone was approved as a treatment for alcohol dependence in 1994
by the U.S. Federal Drug Administration, it has been widely used as a first-line pharmacological
treatment for AUD. As a μ-opioid receptor antagonist, naltrexone blocks alcohol-related
dopamine release in the mid-brain reward system, thereby reducing the reward and
reinforcement associated with alcohol consumption.
Many controlled trials have been carried out over the past three decades to examine the efficacy
of naltrexone on various AUD-related outcomes and several meta-analyses have been carried
out to synthesize the results of these studies. These meta-analyses have generally indicated
moderate to strong efficacy in treating AUD with naltrexone. However, these meta-analyses
included studies that carried out various psychotherapies to augment the naltrexone treatment
of AUD. Two studies [1, 2] had previously examined the effect of adding psychotherapy to
naltrexone treatment in treating AUD, within-study, and concluded that adding psychotherapy
to the naltrexone treatment of AUD did not result in significantly better outcomes. Apart from
these two studies, it remains largely unclear if the significant treatment effect is primarily
attributed to naltrexone alone or the combination of naltrexone and psychotherapy. Such
information would be useful to optimize existing naltrexone interventions on AUD.
To this end, in addition to examining the overall efficacy of naltrexone on AUD, we also
examined the impact of psychotherapy in two different ways. First, we compared the pooled
estimates between studies with and without psychotherapy; then we examined the moderation
effect of psychotherapy on the treatment outcomes. As with previous meta-analyses on AUD
intervention studies, we hypothesized that the meta-analysis would yield significant effect
sizes favoring the use of naltrexone on AUD. Additionally, based on a previous meta-analysis
comparing between pharmacological-only treatment and combined psychotherapy and
pharmacological treatment, we hypothesized that studies of naltrexone treatment combined
with psychotherapy yield significantly better AUD-related outcomes relative to those of
naltrexone alone studies.
Materials And Methods
Data sources and extraction
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
methodology, a search for relevant published literature was carried out on PubMed, Medline
and Cochrane using the keywords “naltrexone”, “low dose naltrexone”, “high dose naltrexone”,
“naltrexone alcohol”, “naltrexone psychotherapy”. This search started on 2nd February 2017
and was last carried out on 30th March 2017. The reference lists of relevant studies were also
manually searched for additional studies. Only articles in English were retrieved. We included
studies of controlled trials involving naltrexone treatment on AUD. Specifically, these studies
must be of an independent group's pretest-posttest design. There were no restrictions on
patients’ age or level of alcohol use. Researches that studied AUD-related outcomes using
experimental/laboratory paradigms were not included in the meta-analysis.
Means and standard deviations (SD) as well as event counts of the trial outcomes, and
information pertaining to the participants (sample size, age, sex, diagnosis), and trial-design
(naltrexone dose, duration and psychotherapy) for each study were entered into a structured
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data abstraction form by the two research assistants. If there were discrepancies among both of
them, the entered data was checked against the source. In cases, where there were multiple
naltrexone treatment groups (i.e., different dosages), these means, SDs and event counts of
these groups were combined using the formulae for combining groups. Due to the multitude of
outcomes studied among the retrieved studies, only data from outcomes, which have been
reported by at least four studies in each of the with and without psychotherapy subgroups, were
extracted. For the purpose of the current study, we define psychotherapy as non-
pharmacological treatment, such as individual and group therapy, psychoeducation, counseling
and skills training, of at least two sessions, aimed at modifying cognition and/or behaviors
associated with alcohol consumption. Hence, interventions that focused solely on adherence or
medication compliance are not considered as psychotherapy. The flow chart for the selection of
studies and data extraction is shown in Figure 1.
FIGURE 1: Selection of studies.
Data Synthesis
For outcomes involving dichotomous variables only at post-treatment, such as the number of
participants who relapsed to heavy drinking or remained abstinent, the log Odds Ratios (OR)
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and their respective sampling variance were calculated using the escalc function in the metafor
package in R. As for continuous outcomes studied both at baseline and post-treatment such as
Gamma-Glutamyl Transferase (GGT) levels and cravings, the raw score single group pretest-
posttest standardized mean difference (SMD) for both the treatment and placebo groups was
computed separately using Formula A1. Following which, the placebo group’s SMD was
subtracted from that of the treatment group to obtain the overall SMD for a particular studied
outcome in the study. The sampling variances of the treatment and placebo subgroups were
then summed to obtain the overall sampling variance for that outcome in the study.
These SMDs and ORs were then pooled and meta-analyzed using random effects models (REM),
to allow the effect sizes to vary across studies. The direction of the effect sizes was coded in a
manner that larger positive effect sizes correspond to larger positive differences (i.e., treatment
– placebo) in raw scores. The Wald test was used to compare the pooled estimates between
studies with and without psychotherapy. Next, a mixed effects model was meta-analyzed with
psychotherapy (coded dichotomously for presence or absence) included as a moderator.
Heterogeneity was measured using the Q statistic; a significant Q statistic suggests that the
variability among the effect sizes is larger than what is expected from subject sampling error
alone. In addition, trim and fill analyses were carried out to assess whether publication bias
had significantly influenced the aggregated effect sizes. Specifically, the trim and fill analyses
determine whether there are missing effect sizes, if so impute the missing effect sizes, and then
recalculate the aggregated effect sizes. Follow-up leave-one-out analyses were carried out to
assess the robustness of the results. These analyses were carried out using the metafor package
in R 3.4.0.
Results
The study and participant characteristics of all included studies are presented in Table 1 and
Table 2, respectively. At least four studies in each of the with or without psychotherapy
subgroups had reported data on abstinence, relapse, cravings, and GGT; these variables were
then included in the meta-analyses. The results of the meta-analysis are shown in Table 3. The
forest plots for the REMs of all studies are presented in Figures 2-5. Significant pooled
estimates were obtained for the REM involving studies with psychotherapy for abstinence and
relapse and all studies, for abstinence, relapse, and GGT. The significant negative effect sizes
for relapse and GGT, and positive effect size for abstinence indicated that participants in the
naltrexone treatment conditions had significantly better outcomes in these areas, relative to
those in the placebo group. With the exception of a significant intercept in the mixed effect
model (MEM) for relapse, none of the parameters in the MEMs was significant for any of the
studied outcomes. Neither were the effect sizes in any of the craving meta-analyses statistically
significant. Finally, none of the Wald test statistics was significant, suggesting that the pooled
estimates of studies with and without psychotherapy were not significantly different.
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Pettinati
et al. [18] 2010 Cognitive behavioral therapy 100 mg/day
14
weeks
≥4 d/d for women;
≥5 d/d for men  
Baltieri et
al. [19]













>5 d/d for men; >4














≥5 d/d for men; ≥4





2006 No psychotherapy 50 mg/day
12
weeks
≥4 d/d for women;




2003 Cognitive behavioral therapy 50 mg/day
6
months
≥4 d/d for women;




2003 Supportive therapy 50 mg/day
6
months
≥4 d/d for women;




2000 Psychosocial treatment 50 mg/day
12
weeks





2001 Coping (group therapy) 50 mg/day
12
weeks






2001 Supportive therapy 50 mg/day
12
weeks






2004 Counseling 50 mg/day
36
weeks
≥ 5 d/o or ≥ 5 dd/w  
Gastpar
et al. [26]
2002 Psychosocial treatment 50 mg/day
12
weeks
≥4 d/d for women;




2001 Psychoeducation 50 mg/day
12
weeks
≥ 5 d/occasion or ≥











≥ 5 dd/w OCDS
Toneatto
et al. [29]
2009 Cognitive behavioral therapy












≥4 d/d for women;
≥6 d/d for men
 
TABLE 1: Study characteristics of included studies.
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d/d = drinks per day; d/o = drinks per occasion; dd/w = drinking days per week; BAC = Breath Alcohol Concentration; OCDS =




Number of participants (% male) Age
Baseline Follow Up Treatment Control
First author Year  Treatment Placebo Treatment Placebo Mean SD Mean SD
Anton et al. [4] 2003
DSM-III-R
AD
68 (69) 63 (73) 68 63 41 10 44 10
Anton et al. [3]
(CBI)
2006a DSM-IV AD 155 (68)
156
(71)
95 100 45.2 10.1 43.2 9.7
Anton et al. [3]
(NP)
2006a DSM-IV AD 154 (68)
103
(67)
96 89 44.4 9.9 44.2 9.2





29 25 19 15 42.8 10.3 38.5 8.8





23 27 18 16     
Oslin et al. [6] 1997
DSM-III-R
AD
21 23 14 13 56.5 6.8 58.9 6.7
Petrakis et al. [7] 2005 DSM-IV AD 59 (100)
64
(100)
46 40 47.7 7.4 46.2 7.3
Volpicelli et al. [8] 1997
DSM-III-R
AD
48 (73) 49 (82) 35 36 39 9 37.9 8.5
Davidson et al. [9] 2004 AUDIT ≥ 8 19 19 16 19 46.5 10.5 50.8 7
Kranzler et al. [10] 2000 DSMIII-R AD 61 (80) 63 (75)   39.7 8.4 41.8 8.1
Monti et al. [11] 2001
DSM-IV
AD/A
64 64       





26 27 17 13     





30 30 19 24     
O'Malley et al. [13] 2008 DSM-IV AD 34 (65) 34 (62) 35 21 42 10.67 38.8 10.41
Oslin [14] 2005 DSM-IV AD 37 (78) 37 (81)   64.2 6.9 62.5 5.6
Pettinati et al. [15] 2006 DSM-IV AD 52 (75) 54 (70) 35 32 41.3 6.8 41.2 7.5
Brown et al. [16] 2009 DSM-IV AD 20 (50) 20 (45) 14 12     
Anton et al. [2]
2005 DSM-IV AD 39 (79) 41 (73) 36 37 44 8 45 11
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(CBT) 
Anton et al. [2]
(MET)
2005 DSM-IV AD 41 (73) 39 (77) 34 28 43 10 43 9
Kranzler et al. [17] 2004 DSM-IV AD 158 (67)
157
(63)
127 118 44.1 9.6 43.6 8.5
Pettinati et al. [18] 2010 DSM-IV AD 49 (67) 39 (56) 29 23 42.9 8.1 43.4 8.9
Baltieri et al. [19] 2008 ICD-10 AD 49 (100)
54
(100)
29 23 44.1 7.2 43.4 8.8
Guardia et al. [20] 2002 DSM-IV AD 101 (72)
101
(77)
61 59 41 8 42 9
Kiefer et al. [21] 2003 DSM-IV AD 40 (78) 40 (68) 22 10 46.1 8.1 45.6 11.1
Morley et al. [22] 2006
DSM-IV
AD/A
53 (72) 61 (64) 36 40 47.6 8.5 42.4 9.3
Balldin et al. [23]
(CBT)
2003 DSM-IV AD 25 (84) 30 (77)   50 7 50 8
Balldin et al.
[23] (ST)
2003 DSM-IV AD 31 (87) 32 (91)   48 8 51 8
Chick et al. [24] 2000
DSM-III-R
AD/A
90 (72) 85 (78) 37 36 43.1 8.3 43.9 9.7
Heinala et al. [25]
(C)
2001 DSM-IV AD 34 33       
Heinala et al. [25]
(ST)
2001 DSM-IV AD 29 25       
Ahmadi et al. [1] 2004 DSM-IV AD 58 58 26 15 42.76 9.58 43.19 8.81
Gastpar et al. [26] 2002
DSM-III-R
AD/A
84 (77) 87 (68) 56 54 43.4 9.9 42 9.6






  47 8 48 8
Latt et al. [28] 2002 DSM-IV AD 56 51 38 36     
Toneatto et al. [29] 2009
DSM-IV
AD/A
27 25 26 25     
Krystal et al. [30] 2001 DSM-IV AD 418 (97)
209
(98)
378 187 48.9 10 49.5 10
TABLE 2: Participant characteristics of included studies.
AUD = Alcohol use disorders; DSM = Diagnostic and Statistic Manual; SD = Standard Deviation; C = Coping; CBT = Cognitive
Behavioral Therapy; ST = Supportive Therapy; NP = No psychotherapy; AD = Alcohol Dependence; AD/A = Alcohol dependence or
abuse; AUDIT = Alcohol Use Disorder Inventory Test; MET = Motivational Enhancement Therapy; CBI = Combined Behavioral
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Intervention.
Model/Parameter K Ntreatment Ncontrol Estimate 95% CI Q
Pwith vs. w/o
psychotherapy
Abstinence        









w/o psychotherapy 4 183 196 1.10 .59, 2.06 5.69
Mixed Effect Model (MEM) 17 954 959   27.70  
Intercept    .07 -.47, .61   
Psychotherapy    .27 -.34, .88   
Relapse        
REM 27 1990 1725 .66*** .57, .77 40.33*  
With psychotherapy 23 1656 1434 .65*** .55, .77 35.59*
.67
w/o psychotherapy 4 334 286 .70* -.68, .98 4.59
MEM 27 1990 1725   41.80*  
Intercept    -.35* -.69 -.02   
Psychotherapy    -.07 -.44, .30   
Gamma Glutamyl Transferase
(GGT)
       
REM 13 554 565 -.16* -.29, -.04 3.74  
With psychotherapy 9 379 389 -.15 -.30, .01 2.37
.74
w/o psychotherapy 4 175 176 -.19 -.41, .03 1.26
MEM 13 554 565   3.29  
Intercept    -.19 -.41, .03   
Psychotherapy    -.05 -.22, .32   
Cravings        
REM 14 626 640 -.11 -.31, .10 2.36  
With psychotherapy 10 457 467 -.19 -.42, .03 15.55
.14
w/o psychotherapy 4 169 173 .14 -.24, .51 4.42
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MEM 14 626 640   23.38*  
Intercept    .14 -.23, .51   
Psychotherapy    -.33 -.76, .10   
TABLE 3: Results of the meta-analyses.
Note: Estimates for REM in the abstinence and relapse models are presented as odds ratios.
K = Number of studies; CI = Confidence intervals; w/o = without; GGT = Gamma-Glutamyl Transferase; REM = Random Effects
Model; MEM = Mixed Effects Model.
*p < .05; **p < .01; ***p < .001.
FIGURE 2: Forest plots of effect sizes for abstinence.
FIGURE 3: Forest plots of effect sizes for relapse.
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FIGURE 4: Forest plots of effect sizes for Gamma-Glutamyl
Transferase.
FIGURE 5: Forest plots of effect sizes for cravings.
The Q statistics indicated that there was significant heterogeneity in the REMs of all studies
and studies with psychotherapy for relapse. Furthermore, there was also significant
heterogeneity in the MEMs for relapse, and cravings. The trim and fill analyses carried out for
all REMs of all studies did not result in any imputation of studies. This suggests that
publication biases were minimal or non-significant. The funnel plots and leave-one-out
analyses are presented in Figures 6-9 and Tables 4-7. In general, the exclusion of any single
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study from the REMs did not alter the statistical significance of any existing pooled estimates;
these estimates remained statistically significant in the REMs for abstinence, relapse, and GGT,
and non-significant in the REM for cravings. These results suggest that the results are generally
robust.
FIGURE 6: Funnel plots of standard errors plotted against
effect sizes for identification of publication bias for abstinence.
FIGURE 7: Funnel plots of standard errors plotted against
effect sizes for identification of publication bias for relapse.
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FIGURE 8: Funnel plots of standard errors plotted against
effect sizes for identification of publication bias for Gamma-
Glutamyl Transferase.
FIGURE 9: Funnel plots of standard errors plotted against
effect sizes for identification of publication bias for cravings.
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 Study/Year Estimate P​Estimate 95% CI Q PQ
1 O'Malley et al. [5] (C)(1992) 0.31 0.0227 0.04 0.57 25.22 0.0471
2 O'Malley et al. [5] (ST) (1992) 0.24 0.0331 0.02 0.46 18.82 0.2220
3 Oslin et al. [6] (1997) 0.31 0.0209 0.05 0.58 25.26 0.0465
4 Volpicelli et al. [8] (1997) 0.31 0.0280 0.03 0.59 25.21 0.0472
5 Anton et al. [4] (2003) 0.29 0.0380 0.02 0.56 24.56 0.0562
6 Kranzler et al. [10] (2000) 0.35 0.0076 0.09 0.61 23.18 0.0803
7 Chick et al. [24] (2000) 0.34 0.0134 0.07 0.62 24.37 0.0591
8 Morris et al. [27] (2001) 0.29 0.0275 0.03 0.55 24.62 0.0552
9 Gastpar et al. [26] (2002) 0.34 0.0201 0.05 0.62 24.92 0.0511
10 Kiefer et al. [21] (2003) 0.25 0.0326 0.02 0.48 19.63 0.1867
11 Kranzler et al. [17] (2004) 0.27 0.0449 0.01 0.53 23.81 0.0683
12 Petrakis et al. [7] (2005) 0.34 0.0137 0.07 0.62 24.39 0.0588
13 Oslin [14] (2005) 0.35 0.0068 0.10 0.6 22.76 0.0893
14 Morley et al. [22] (2006) 0.33 0.0149 0.07 0.6 24.71 0.0539
15 O'Malley et al. [13] (2008) 0.26 0.0325 0.02 0.5 22.11 0.1048
16 Baltieri et al. [19] (2008) 0.33 0.0173 0.06 0.61 24.93 0.0509
17 Pettinati et al. [18] (2010) 0.34 0.0135 0.07 0.6 24.51 0.0570
TABLE 4: Leave-one-out sensitivity analysis for abstinence.
C = Coping; ST = Supportive Therapy.
 Study Estimate P​Estimate 95% CI Q PQ
1 O'Malley et al. [5] (C)(1992) -0.44 <.0001> -0.59 -0.29 33.74 0.1417
2 O'Malley et al. [5] (ST) (1992) -0.44 <.0001> -0.58 -0.29 35.76 0.0961
3 Anton et al. [3] (CBI) (2006) -0.44 <.0001> -0.59 -0.28 41.27 0.0292
4 Anton et al. [3] (NP) (2006) -0.42 <.0001> -0.57 -0.27 41.95 0.0248
5 Oslin et al. [6] (1997) -0.41 <.0001> -0.56 -0.26 41.01 0.0310
6 Volpicelli et al. [8] (1997) -0.41 <.0001> -0.56 -0.26 41.42 0.0282
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7 Anton et al. [4] (2003) -0.39 <.0001> -0.54 -0.24 40.09 0.0382
8 Chick et al. [24] (2000) -0.41 <.0001> -0.56 -0.26 41.96 0.0248
9 Krystal et al. [30] (2001) -0.41 <.0001> -0.58 -0.25 41.97 0.0247
10 Heinala et al. [25] (C)(2001) -0.43 <.0001> -0.58 -0.28 35.02 0.1111
11 Heinala et al. [25] (ST) (2001) -0.42 <.0001> -0.56 -0.27 41.94 0.0249
12 Morris et al. [27] (2001) -0.41 <.0001> -0.56 -0.26 41.94 0.0249
13 Guardia et al. [20] (2002) -0.40 <.0001> -0.55 -0.25 40.29 0.0366
14 Gastpar et al. [26] (2002) -0.44 <.0001> -0.59 -0.29 40.13 0.0379
15 Latt et al. [28] (2002) -0.40 <.0001> -0.55 -0.25 41.09 0.0304
16 Kiefer et al. [21] (2003) -0.40 <.0001> -0.55 -0.25 39.93 0.0396
17 Balldin et al. [23] (2003) (CBT) -0.41 <.0001> -0.56 -0.27 41.81 0.0257
18 Balldin et al. [23] (2003) (ST) -0.42 <.0001> -0.57 -0.28 40.26 0.0368
19 Kranzler et al. [17] (2004) -0.41 <.0001> -0.56 -0.26 41.79 0.0258
20 Ahmadi et al. [1] (2004) -0.40 <.0001> -0.55 -0.25 40.78 0.0326
21 Oslin [14] (2005) -0.43 <.0001> -0.58 -0.28 40.76 0.0328
22 Anton et al. [2] (2005) (CBT) -0.40 <.0001> -0.55 -0.25 40.76 0.0328
23 Anton et al. [2] (2005) (MET) -0.41 <.0001> -0.56 -0.26 41.94 0.0249
24 Morley et al. [22] (2006) -0.44 <.0001> -0.59 -0.29 40.07 0.0384
25 O'Malley et al. [13] (2008) -0.41 <.0001> -0.56 -0.26 41.15 0.0299
26 Toneatto et al. [29] (2009) -0.41 <.0001> -0.56 -0.26 40.33 0.0362
27 Pettinati et al. [18] (2010) -0.42 <.0001> -0.57 -0.28 41.56 0.0272
28 Monti et al. [11] (2001) -0.42 <.0001> -0.57 -0.27 41.89 0.0252
TABLE 5: Leave-one-out sensitivity analysis for relapse.
C = Coping; ST = Supportive Therapy; CBI = Combined Behavioral Intervention; NP = No psychotherapy; CBT = Cognitive Behavioral
Therapy; MET = Motivational Enhancement Therapy.
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 Study/Year Estimate P​Estimate 95% CI Q PQ
1 Anton et al. [4] (2003) -0.16 0.0203 -0.29 -0.02 3.74 0.9769
2 Petrakis et al. [7] (2005) -0.16 0.0221 -0.29 -0.02 3.71 0.9777
3 Volpicelli et al. [8] (1997) -0.15 0.0229 -0.28 -0.02 3.60 0.9802
4 O'Malley et al. [12] (2003) (PCM) -0.15 0.0243 -0.28 -0.02 2.94 0.9915
5 O'Malley et al. [12] (2003) (CBT) -0.17 0.0088 -0.30 -0.04 3.14 0.9887
6 O'Malley et al. [13] (2008) -0.17 0.0091 -0.30 -0.04 3.24 0.9871
7 Brown et al. [16] (2009) -0.16 0.0125 -0.29 -0.03 3.71 0.9776
8 Baltieri et al. [19] (2008) -0.15 0.0228 -0.28 -0.02 3.62 0.9798
9 Kiefer et al. [21] (2003) -0.16 0.0170 -0.29 -0.03 3.73 0.9772
10 Balldin et al. [23] (2003) (CBT) -0.16 0.0125 -0.29 -0.04 3.69 0.9781
11 Balldin et al. [23] (2003) (ST) -0.15 0.0231 -0.28 -0.02 3.27 0.9867
12 Morris et al. [27] (2001) -0.18 0.0065 -0.32 -0.05 2.59 0.9951
13 Latt et al. [28] (2002) -0.15 0.0207 -0.29 -0.02 3.68 0.9783
TABLE 6: Leave-one-out sensitivity analysis for Gamma-Glutamyl Transferase.
PCM = Primary Care Management; CBT = Cognitive Behavioral Therapy.
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 Study/Year Estimate P​Estimate 95% CI Q PQ
1 Anton et al. [4] (2003) -0.09 0.4124 -0.31 0.13 22.94 0.0282
2 Davison et al. [9] (2004) -0.14 0.1903 -0.34 0.07 21.14 0.0484
3 Kranzler et al. [10] (2000) -0.05 0.6108 -0.23 0.13 17.18 0.1430
4 O'Malley et al. [12] (2003) (PCM) -0.11 0.3018 -0.33 0.10 23.28 0.0254
5 O'Malley et al. [12] (2003) (CBT) -0.12 0.2539 -0.34 0.09 22.72 0.0302
6 O'Malley et al. [13] (2008) -0.09 0.4202 -0.30 0.13 22.70 0.0304
7 Brown et al. [16] (2009) -0.08 0.4584 -0.28 0.12 20.37 0.0603
8 Baltieri et al. [19] (2008) -0.11 0.3152 -0.32 0.10 23.36 0.0249
9 Guardia et al. [20] (2002) -0.12 0.2898 -0.35 0.10 22.61 0.0312
10 Kiefer et al. [21] (2003) -0.11 0.3106 -0.33 0.11 23.29 0.0253
11 Morley et al. [22] (2006) -0.15 0.1115 -0.35 0.04 18.49 0.1016
12 Balldin et al. [23] (2003) (CBT) -0.06 0.5330 -0.26 0.13 19.46 0.0779
13 Balldin et al. [23] (2003) (ST) -0.10 0.3821 -0.32 0.12 23.24 0.0258
14 Latt et al. [28] (2002) -0.13 0.1999 -0.34 0.07 21.49 0.0437
TABLE 7: Leave-one-out sensitivity analysis for cravings.
PCM = Primary Care Management; CBT = Cognitive Behavioral Therapy.
Discussion
The current study examined the hypothesis that naltrexone is efficacious in treating AUD and
psychotherapy on top of naltrexone significantly augments AUD-related treatment outcomes.
In relation to former, our results have generally indicated that naltrexone has been efficacious
in treating AUD. Specifically, the pool estimates indicated significant treatment effects in
improving self-reported alcohol consumption outcomes such as abstinence, relapse as well as
the objectively measured GGT, which is a widely used and highly specific biomarker for
excessive alcohol consumption. However, there was not a significant treatment effect on
cravings. In relation to the second hypothesis, adding psychotherapy to the naltrexone
treatment of AUD did not significantly augment treatment outcomes; the combined treatment
of psychotherapy and naltrexone was not significantly better than naltrexone alone.
The non-significant difference in treatment outcomes between studies with and without
psychotherapy is noteworthy considering that previous meta-analytic research had found
combined treatments significantly more effective than pharmacological treatment alone in
treating mood and anxiety disorders. Nevertheless, while previous meta-analyses have noted
significant and large treatment effects associated with psychotherapy among these affective
disorders, psychotherapy has been less successful with AUDs. Meta-analyses have generally
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reported small and non-significant treatment effects associated with psychotherapy on AUD.
Given these weak effects, one would not expect the addition of psychotherapy to significantly
augment the naltrexone treatment of AUD. Indeed, researchers who investigated such a
hypothesis within-study did not find significant differences between combined treatment and
naltrexone-only treatment in influencing subsequent AUD outcomes [2, 3]. One may be
concerned at the large variety of psychotherapies carried out across studies, thus rendering it
difficult to interpret or generalize these results to the different adjunctive psychotherapies.
This may be the case for the meta-analyzed relapse outcome, which was associated with
significant heterogeneity. Notwithstanding the slight variation in the definition of relapse
across studies, it may be possible that certain therapies when combined with naltrexone yield
much better treatment outcomes than others. Nevertheless, despite the wide variety of
psychotherapies carried out across the different studies, the results among studies with
psychotherapy were not significantly heterogeneous, at least in relation to abstinence, GGT and
cravings. Assuming the naltrexone effect is constant across study, this may hint to the dodo
bird verdict – all psychotherapies, regardless of their theoretical orientations, produced similar
outcomes. Regardless, future researchers may consider comparing treatment outcomes
between various psychotherapies in combination with naltrexone to verify such an
interpretation.
It is also interesting that while naltrexone had resulted in significantly improved treatment
outcomes in terms of self-reported measures and biomarkers of alcohol consumption, it did
not seem to have a significant treatment effect in reducing alcohol-related cravings. There may
be two explanations for this. First, while naltrexone reportedly modulates the dopaminergic
activity in the mid-brain reward system in an attempt to inhibit the reinforcement associated
with alcohol consumption, it does little to alleviate alcohol-related cravings which are largely
associated with activity in the prefrontal and limbic regions of the brain. Second, it is plausible
that alcohol-related cravings will decrease on its own even without any naltrexone treatment
and this decrease will therefore mask the naltrexone treatment effect, if any at all on cravings.
Indeed, we observed that several studies reported significant decreases (with respect to
baseline) in cravings among placebo groups which were comparable to those of the naltrexone
treatment groups. Furthermore, this decrease cannot be explained by the adjunctive
psychotherapy in most of the included studies since it was not a significant moderator in the
MEM; the pooled estimates relating to the decrease in cravings were also similar between
studies with and without psychotherapy.
These findings present a key implication in the treatment of AUD. These results suggest that it
is not necessary for adjunctive psychotherapy to be carried out on top of naltrexone in the
treatment of AUD. From a resource-allocation perspective, given that individual psychotherapy
is a relatively time- and resource-consuming process, the resources associated with such
adjunctive psychotherapies can be conserved, or instead should be directed at other clinical
populations, such as those with depression and anxiety disorders, in which psychotherapy
would be a lot more beneficial.
The current results are subjected to three major limitations. Firstly, given the very limited
number of studies on naltrexone treatment without psychotherapy, their pooled estimates may
not reliably reflect the effect of naltrexone treatment alone. More ‘naltrexone-only’
intervention studies should be carried out such that future meta-analyses can robustly compare
the AUD treatment outcomes between combined-intervention and naltrexone-only treatments.
Secondly, it is possible that between-study differences in methodology or participants’
characteristics among the included studies may confound the inclusion of psychotherapy in
influencing treatment outcomes. Future intervention studies on AUD should be carried out to
examine the inclusion of psychotherapy on top of naltrexone treatment within-study, such that
stronger conclusions relating to the addition of psychotherapy on top of naltrexone can be
made. Thirdly, the manner in which the additive effects of psychotherapy were studied in the
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current meta-analysis was less than optimal, given that we have simply compared studies with
or without psychotherapy, instead of studies with psychotherapy or a control condition for
psychotherapy. Furthermore, unlike the naltrexone condition, the psychotherapy conditions
were not randomly assigned across all participants. This might raise concerns relating to
whether psychotherapy effects were genuine or attributable to psychotherapy-placebo effects.
Finally, as a result of our study inclusion criteria, such as English language studies only and
including outcomes studied by three studies without therapy, we excluded a large number of
studies, including one with a large sample. This creates a selection bias and may raise concerns
relating to the generalizability of the results.
Conclusions
Naltrexone treatment is efficacious in reducing alcohol consumption, but not reducing
cravings. Adding psychotherapy on top naltrexone did not result in any significant additional
benefit for AUD patients.
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